# RING - Rituximab for Lupus Nephritis With Remission as a Goal

> **NCT01673295** · PHASE3 · UNKNOWN · sponsor: **Frédéric A. Houssiau, MD, PhD** · enrollment: 194 (estimated)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** RTX infusions
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT01673295
- **Lead sponsor:** Frédéric A. Houssiau, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2015-11
- **Final completion:** 2016-11
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2015-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673295, "RING - Rituximab for Lupus Nephritis With Remission as a Goal". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01673295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*